Matt T. Wiltermuth

Matt T. Wiltermuth

Partner

Technology Transactions

Strategic Commercial and IP Transactions

Matt represents clients in collaboration, technology acquisition, licensing, mergers and acquisitions, research and development, manufacturing, and distribution arrangements.
A Focus on Scientific Clients

Matt's clients are primarily pharmaceutical, biotechnology, medical device, and life sciences companies.

Matt Wiltermuth is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. His practice focuses on representing clients in strategic commercial and intellectual property transactions, including collaboration, technology acquisition, licensing, mergers and acquisitions, research and development, manufacturing, and distribution arrangements, primarily in the pharmaceutical, biotechnology, medical device, and life sciences industries.

Before attending law school, Matt was a chemical engineer at 3M Company, conducting product and process development.

Matt is practicing virtually in Wisconsin, where he is licensed.

Experience

Before attending law school, Matt was a chemical engineer at 3M Company, conducting product and process development.

Matt is practicing virtually in Wisconsin, where he is licensed.

Education

J.D., New York University School of Law, 2009Cum Laude
B.S., Chemical Engineering, University of Minnesota, 2001Summa Cum Laude

Admissions

State Bar of California
State Bar of Wisconsin

Credentials

Education

J.D., New York University School of Law, 2009Cum Laude
B.S., Chemical Engineering, University of Minnesota, 2001Summa Cum Laude

Admissions

State Bar of California
State Bar of Wisconsin

Representative Matters

Matt has represented clients in connection with the below matters:

Alector in its collaboration with GSK
Arcellx in its collaboration with Kite
Caribou Biosciences in its cross-license with DuPont
Cephea Valve Technologies in its collaboration with and acquisition by Abbott
Kallyope in its collaborations with Novo Nordisk and Sosei Heptares
Mammoth Biosciences in its collaborations with Bayer, Vertex, and Horizon Discovery Group
Mesoblast in its collaboration with Grünenthal
Nanjing Legend Biotech in its collaboration with Janssen
Peloton Therapeutics in its collaboration with Merck
Taiho Pharmaceutical Co. Ltd. in its acquisition of Cullinan Pearl and collaboration with Cullinan Oncology
Tenaya Therapeutics in its initial public offering
Verily Life Sciences in its collaborations with Procter & Gamble and Sanofi
Vividion Therapeutics in its collaboration with Roche

Matters

Representative Matters

Matt has represented clients in connection with the below matters:

Alector in its collaboration with GSK
Arcellx in its collaboration with Kite
Caribou Biosciences in its cross-license with DuPont
Cephea Valve Technologies in its collaboration with and acquisition by Abbott
Kallyope in its collaborations with Novo Nordisk and Sosei Heptares
Mammoth Biosciences in its collaborations with Bayer, Vertex, and Horizon Discovery Group
Mesoblast in its collaboration with Grünenthal
Nanjing Legend Biotech in its collaboration with Janssen
Peloton Therapeutics in its collaboration with Merck
Taiho Pharmaceutical Co. Ltd. in its acquisition of Cullinan Pearl and collaboration with Cullinan Oncology
Tenaya Therapeutics in its initial public offering
Verily Life Sciences in its collaborations with Procter & Gamble and Sanofi
Vividion Therapeutics in its collaboration with Roche

Recent Insights

Client Highlights

On December 9, 2022, clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop and commercialize Arcellx’s lead late-stage myeloma candidate. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.

Learn More

Client Highlights

On August 3, 2021, Tenaya Therapeutics, a biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease, announced the closing of its underwritten, upsized initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,800,000 additional shares of its common stock, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering were $207.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Tenaya. All shares in the offering were offered by Tenaya. The shares began trading on the Nasdaq Global Select Market on July 30, 2021, under the ticker symbol “TNYA.”

Learn More